An integrated model for determining causes of poor oral drug absorption

Pharmaceutical Research

Volumn 16, Issue 12, 1999, Pages 1883-1887

  Yu, Lawrence X ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Absorption; Dissolution; Modeling; Permeation; Small intestinal transit

Indexed keywords

DIGOXIN; GRISEOFULVIN; PANADIPLON;

ANALYTIC METHOD; ARTICLE; COMPUTER SIMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; INTESTINE TRANSIT TIME; MODEL; PRIORITY JOURNAL;

EID: 0033427120     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018911728161     Document Type: Article

References (19)

1. L. X. Yu, J. R. Crison, E. Lipka, and G. L. Amidon. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Del. Rev. 19:359-376 (1996).
2. L. X. Yu and G. L. Amidon. Characterization of small intestinal transit time distribution in humans. Int. J. Pharm. 171:157-163 (1998).
3. L. X. Yu and G. L. Amidon. Saturable small intestinal drug absorption in humans: modeling and explanation of the cefatrizine data. Eur. J. Pharm. Biopharm. 45:199-203, 1998.
4. M. Mayersohn. Principles of drug absorption. In G. S. Banker and C. T. Rhodes (eds.), Modern Pharmaceutics, 2nd ed., Marcel Dekker: New York, 1990, pp. 23-90.
5. R. J. Hintz and K. C. Johnson. The effect of particle size distribution on the dissolution rate and oral absorption. Int. J. Pharm. 51:9-17, 1989.
6. K. A. Kelly. In L. R. Johnson (Editor-in-Chief), Physiology of the Gastrointestinal Tract, Vol 1, Raven Press, New York, 1981, pp. 393-410.
7. J. B. Dressman and D. Fleisher. Mixing-tank model for predicting dissolution rate control of oral absorption. J. Pharm. Sci. 75:109-116 (1986).
8. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
9. D. Z. D'Argenio and A. Schumitzky. Adapt II: Mathematical Software for Pharmacokinetic/Pharmacodynamic Systems Analysis, University of Southern California, Los Angles, 1992.
10. A. Astrorri, G. Bianchi, G. LaCanna, D. Assanelli, O. Visioli, and A. Marzo. Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients. J. Pharm. Sci. 68:104-106 (1979).
11. B. F. Johnson, J. O'Grady, and C. Bye. The influence of digoxin particle size on absorption of digoxin and the effect of porpantheline and metoclopramide. Br. J. Clin. Pharmac. 5:465-467 (1978).
12. A. J. Jounela, P. J. Pentikainen, and A. Sothmann. Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8:365-370 (1995).
13. T. R. D. Shaw and J. E. Carless. The effect of particle size on the absorption of digoxin. Eur. J. Clin. Pharmacol. 7:269-273 (1974).
14. D. H. Huffman and D. L. Azarnoff. Absorption of orally given digoxin preparations. JAMA. 222:957-960 (1972).
15. V. Manninen, A. Apajalahti, J. Melin, and M. Karesoja. Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet, 398-400 (1973).
16. T. Gramatte. Griseofulvin absorption from different sites in the human small intestine. Biopharm. Drug Dis. 15:747-759 (1994).
17. W. L. Chiou and S. Riegelman. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J. Pharm. Sci. 60:1376-1380 (1971).
18. P. Kabasakalian, M. Katz, B. Rosenkrantz, and E. Townley. Parameters affecting absorption of griseofulvin in a human study using urinary metabolite excretion data. J. Pharm. Sci. 59:595-600 (1970).
19. T. Nishihata, M. Ishizaka, S. Yokohama, A. C. Martino, and R. E. Gordon. Effects of particle size of bulk drug and food on the bioavailability of U-78875. Drug Dev. Ind. Pharm. 19:2679-2698 (1993).